Clinical trials: Localised Prostate Cancer, active
Localized Prostate Carcinoma
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
Patients with prostate cancer who are candidates for stereotactic radiotherapy to the prostate and seminal vesicles will undergo staging exams, which will include prostate specific membrane antigen (PSMA) positron emission…
- Trial name
- PRO-FAST (NCT05936736)
- Testing
- prostate SBRT
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Intermediate Risk Prostate Cancer (Diagnosis), Prostate Cancer
Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT07674225)
- Testing
- Prostate radical radiotherapy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
New Treatment Modalities for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of four of the nowadays most established primary treatments for patients with clinically localized prostate cancer (active surveillance, robot-assisted radical…
- Trial name
- TTOPROST/OBS (NCT05523856)
- Testing
- Active Surveillance, Robot-Assisted Radical Prostatectomy, Intensity-Modulated Radiotherapy
- Volunteers
- 480 people
- Sponsor
- Fundacion IMIM
Prostate Cancer
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer
As the most common carcinoma in men, prostate cancer is a significant tumor entity in oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent therapy alternative in the non-metastatic primary…
- Trial name
- SMILE (NCT04845503)
- Testing
- MR-guided Radiotherapy
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer.
- Trial name
- PrTK03 (NCT01436968)
- Testing
- Aglatimagene besadenovec + valacyclovir
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 711 people
- Sponsor
- Candel Therapeutics, Inc.
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Prostate Cancer
Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer
The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days.
- Trial name
- HERMES (NCT04595019)
- Testing
- SBRT
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Adenocarcinoma
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is…
- Trial name
- BiolenRT (NCT04943536)
- Testing
- bicalutamide, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alessa Therapeutics Inc.
Prostate Carcinoma
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
The purpose of this study is to evaluate the dose of High Dose Rate (HDR) brachytherapy chosen for this study as well as a commonly used alternate form of brachytherapy called low dose rate (or seed) brachytherapy.
- Trial name
- NCT02960087
- Testing
- Low dose rate brachytherapy, High dose rate brachytherapy
- Where
- 7 sites in Canada
- Volunteers
- 334 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making
In this pilot study, the investigators will show feasibility of the NLP-based feedback system in 20 consultations of men with newly diagnosed prostate cancer.
- Trial name
- NCT05923684
- Testing
- NLP-based Feedback
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Prostate Cancer, Localized Prostate Carcinoma
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea works in finding prostate cancer that exhibits…
- Trial name
- NCT02526368
- Testing
- Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Ivan de Kouchkovsky, MD
Prostate Cancer
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
- Trial name
- VAPOR 2 (NCT05683691)
- Testing
- Vanquish System
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Francis Medical Inc.
Prostate Cancer
SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial
This study will test a web-based supportive care program called the Support, Communication, and Information Program for Prostate Cancer - Interactive (SCIPI).
- Trial name
- SCIPI (NCT07280897)
- Testing
- SCIPI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Localized Prostate Cancer
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized…
- Trial name
- 62SPECIAL (NCT07792993)
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Regina Elena Cancer Institute
Prostate Cancer
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade).
- Trial name
- uTRACE-101 (NCT06474806)
- Testing
- 64Cu-DOTA-AE105
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 168 people
- Sponsor
- Curasight
Prostate Cancer, Localized Prostate Carcinoma
PSMA-Guided Ablation of the Prostate
The goal of this phase 2 multicenter randomized controlled trial is to study the accuracy of second generation prostate specific membrane antigen (PSMA) positron emission tomography (PET; utilizing 18F-PSMA-1007) compared to…
- Trial name
- P-GAP (NCT06003556)
- Testing
- PSMA-1007 Positron Emission Tomography (PET) scan
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Prostate Cancer, Localized Prostate Carcinoma
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer.
- Trial name
- MIDAS (NCT07644598)
- Testing
- Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Georgetown University
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
This clinical trial studies the side effects of computed tomography (CT)-guided stereotactic body radiation therapy (SBRT) with intrafraction motion monitoring and to see how well it works in treating patients with prostate…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- ILLUSION (NCT06995053)
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy
This clinical trial studies whether a new multi-layer perinatal tissue allograft, MLG-Complete (Trademark), can be used to improve complications after nerve-sparing robot-assisted radical prostatectomy (RARP) in patients with…
- Conditions
- Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- RAP (NCT06940271)
- Testing
- Allografting, Survey Administration
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic